Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

May 5, 2026

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

March 31, 2026

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer

March 25, 2026

Financial Events

Imunon First Quarter 2026 Financial Results

May 12, 2026 at 11:00 AM EDT

Presentation at the MedInvest Biotech and Pharma Investor Conference

April 1, 2026